Evidence map›Paper›PMID 42116828›Full record

ArticleClinical epidemiology2026

Maternal Group B

Erzsébet Horváth-Puhó, Theresa Lamagni, Paul T Heath, Merijn W Bijlsma, Malene Risager Lykke, Kirsty Le Doare, Brechje De Gier, Simon R Procter, Asma Khalil, Proma Paul and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Erzsébet Horváth-PuhóDepartment of Clinical Epidemiology and Center for Population Medicine, Aarhus University Hospital and Aarhus University, Aarhus, Denmark.ORCID 0000-0002-3594-2212
Theresa LamagniAntimicrobial Resistance & Healthcare Associated Infection Division, UK Health Security Agency, London, UK.
Paul T HeathCentre for Neonatal and Paediatric Infection & Vaccine Institute, City St George's, University of London, London, UK.
Merijn W BijlsmaDepartment of Neurology, Amsterdam Neuroscience, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Malene Risager LykkeDepartment of Clinical Epidemiology and Center for Population Medicine, Aarhus University Hospital and Aarhus University, Aarhus, Denmark.
Kirsty Le DoareCentre for Neonatal and Paediatric Infection & Vaccine Institute, City St George's, University of London, London, UK.
Brechje De GierCenter for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Amsterdam, the Netherlands.
Simon R ProcterLondon School of Hygiene & Tropical Medicine, London, UK.
Asma KhalilCentre for Neonatal and Paediatric Infection & Vaccine Institute, City St George's, University of London, London, UK.
Proma PaulLondon School of Hygiene & Tropical Medicine, London, UK.ORCID 0000-0003-0258-1040
Andrew Norman YoungCentre for Neonatal and Paediatric Infection & Vaccine Institute, City St George's, University of London, London, UK.
Henrik T SørensenDepartment of Clinical Epidemiology and Center for Population Medicine, Aarhus University Hospital and Aarhus University, Aarhus, Denmark.ORCID 0000-0003-4299-7040
Joy E LawnDepartment of Clinical Epidemiology and Center for Population Medicine, Aarhus University Hospital and Aarhus University, Aarhus, Denmark.ORCID 0000-0002-4573-1443

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Group B Objective: Recent progress in the development of maternal GBS vaccines adds urgency to the need for comprehensive surveillance data. The aim of this study is to describe advances in routine health information systems and record linkage offer new opportunities for robust monitoring and research on GBS outcomes, both before and after vaccine roll-out. Approach: This review article identifies crucial research gaps, proposes priority outcomes that should be monitored, and highlights opportunities to use routine data from three European countries (Denmark, the Netherlands, the United Kingdom) to harmonise data and strengthen the evidence base to inform national GBS vaccine policy decisions. Conclusion: Strengthening and harmonising routine data collection across Europe and globally will be essential to maximize and measure the benefits of a maternal GBS vaccination.

Indexed as

Group B Streptococcushealth registriesmaternal vaccines

Identifiers

PMID42116828
PMCPMC13157838

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.